Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPMX-T003 in Polycythemia Vera
NCT05074550Phase 1Unknown
- Sponsor
- Perseus Proteomics Inc.
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PPMX-T003 in polycythemia vera (PV), sponsored by Perseus Proteomics Inc. Primary endpoint: Number of Patients Experiencing Treatment-emergent Adverse Events at 45 weeks. Status: unknown.
02
Drugs
PPMX-T003
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05074550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074550.